Microcap Ledger Glucotrack, Inc. $GCTK
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Surgical & Medical Instruments & Apparatus
- Headquarters
- Rutherford, NJ
- Fiscal year end
- December 31
- Shares outstanding
- 10,578,822 [10-Q 2026-08-14]
What the company doesAI summary of filing
Glucotrack, Inc. is a clinical-stage medical device company developing an implantable continuous blood glucose monitor (CBGM) for persons with Type 1 diabetes and Type 2 diabetes using insulin or at risk for hypoglycemia. The company's device uses an intravascular approach with a subcutaneous implant connected to a lead placed directly into a blood vessel, designed to provide continuous blood glucose measurements with minimal calibration and no wearable component. Glucotrack completed a first-in-human acute study in Brazil in early 2025 demonstrating safety and functionality, obtained ISO 13485 certification in 2024, and is preparing an Investigational Device Exemption submission to the FDA in the second quarter of 2026 to initiate a U.S. feasibility study expected to launch in the second half of 2026. The company is pre-revenue and generates no product sales at this stage. [10-K 2026-03-30]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | — | −$8.15M | −$7.66M | $1.12M | [10-Q 2026-08-14] |
| FY ended Dec 2025 | — | −$19.39M | −$15.24M | $7.38M | [DEF 14A 2026-07-17] |
| FY ended Dec 2024 | — | −$22.58M | −$12.49M | $5.62M | [DEF 14A 2026-07-17] |
- Quarterly cash burn
- −$3.83M
- Cash runway Estimate
- ~0.9 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-03 | 5,772,026 | [10-Q 2024-11-14] |
| 2025-03-31 | 25,585,853 | [10-K 2025-03-31] |
| 2025-05-14 | 28,642,809 | [10-Q 2025-05-14] |
| 2025-08-14 | 899,410 | [10-Q 2025-08-14] |
| 2025-11-13 | 910,688 | [10-Q 2025-11-13] |
| 2026-03-30 | 1,944,279 | [10-K 2026-03-30] |
| 2026-05-14 | 6,259,279 | [10-Q 2026-05-14] |
| 2026-08-14 | 10,578,822 | [10-Q 2026-08-14] |
- Shelf registration
- S-1 filed 2026-09-18; no effectiveness notice found in EDGAR [S-1 2026-09-18]
Listing status
Current status: 3 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2026-05-15. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2026-05-15 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2026-05-15] |
| 2025-04-04 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-04-04] |
| 2024-12-31 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2024-12-31] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-09-28 | 8-K | Material agreement entered |
| 2026-09-24 | 424B5 | Prospectus or prospectus supplement |
| 2026-09-24 | 8-K | Material agreement entered; Regulation FD disclosure |
| 2026-09-23 | 8-K | Regulation FD disclosure |
| 2026-09-18 | 8-K | Director or officer change |
| 2026-09-18 | S-1 | Registration statement |
| 2026-09-14 | 8-K | Material agreement entered; Shareholder vote results |
| 2026-09-11 | 8-K | Material agreement entered; New financial obligation; Unregistered sale of equity |
| 2026-09-09 | 8-K | Material agreement entered; New financial obligation; Unregistered sale of equity |
| 2026-09-02 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-08-28 | 8-K | Charter, bylaws or fiscal year change; Other events |
| 2026-08-28 | 8-K | Acquisition or disposition completed |
Alerts for $GCTK
Email me when Glucotrack, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.